StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ ADXS opened at $0.03 on Friday. The stock has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.70. The firm has a 50-day moving average of $0.04 and a 200-day moving average of $0.07. Ayala Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $1.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.